Arginine deiminase (ADI) and arginase (Arg1) have emerged as promising agents in the therapeutic armamentarium against glioma, with demonstrated anti-glioma toxicity and a reliable safety profile in both in vitro and in vivo experiments. This evidence concerns the gene ARG1 and central nervous system cancer.